Clinical Trials Logo

CD19+ Acute Leukemia clinical trials

View clinical trials related to CD19+ Acute Leukemia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02028455 Active, not recruiting - Clinical trials for CD19+ Acute Leukemia

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

Start date: February 11, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Patients with relapsed or refractory leukemia often develop resistance to chemotherapy. For this reason, we are attempting to use T cells obtained directly from the patient, which can be genetically modified to express a chimeric antigen receptor (CAR). The CAR enables the T cell to recognize and kill the leukemic cell through the recognition of CD19, a protein expressed of the surface of the leukemic cell in patients with CD19+ leukemia. This is a phase 1/2 study designed to determine the maximum tolerated dose of the CAR+ T cells as well as to determine the efficacy. The phase 1 cohort is restricted to those patients who have already had an allogeneic hematopoietic cell transplant (HCT). The phase 2 is open to all patients regardless of having a history of HCT.